Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in Breast and Gastric Cancers The Phase 1 First-In-Human study is designed to assess the safety, tolerability & preliminary clinical activity of 177Lu-RAD202 in individuals with HER2-positive metastatic solid tumors Ten HER2-positive breast cancer patients previously dosed in a Phase 1 diagnostic study demonstrated the safety and biodistribution of 177Lu-RAD202, validating its potential for the treatment of advanced HER2-expressing cancersSYDNEY, Dec. 20, 2024 (GLOBE NEWSWIRE) — Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has...

RESTON, Va., Dec. 20, 2024 (GLOBE NEWSWIRE) — Comscore (NASDAQ: SCOR), a trusted partner for planning, transacting, and evaluating media across platforms, today announced the expansion of its partnership with Gray Media, one of the largest TV station groups in the United States, in a multi-year agreement. Comscore will continue as a key local measurement currency provider for Gray Media and provide additional advanced demographics as well as more precise audience insights across screens. This enhanced partnership demonstrates Comscore’s commitment to delivering innovative, audience-centric solutions that help broadcasters like Gray and their advertisers drive revenue growth and optimize campaign performance. “We appreciate Comscore’s continued advancements in audience measurement and are pleased to roll out these solutions across...

In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placebo While there was a favorable trend for incidence of varices in the primary end point intent-to-treat population, belapectin did not achieve statistical significance Belapectin was overall well tolerated with no safety signals; incidence of adverse events and serious adverse events were comparable across the three cohorts Additional data to be presented in early 2025NORCROSS, Ga., Dec. 20, 2024 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced results from its global clinical trial NAVIGATE evaluating belapectin in patients with Metabolic Dysfunction-Associated...

HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) —Trading to continue under ticker symbol “CYTOF” No reverse stock split plannedAltamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB: CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that on December 18, 2024 it received notice that the Nasdaq Hearings Panel (the “Panel”) had determined to delist the Company’s common shares from The Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s failure to comply with Rule 5550(a)(2) of Nasdaq’s Listing Rules. The Rule requires listed securities to maintain a minimum bid price of $1.00 per share. The Company’s common shares will be delisted from Nasdaq at the open of trading on December 20, 2024 and...

SALINAS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) — Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California-born cannabis company with advanced production capabilities including extraction, manufacturing, and distribution, announces the appointment of Philippe Faraut as Chief Financial Officer of the Company, effective immediately. “We are excited to welcome Philippe as our new CFO,” said Mark Ainsworth, CEO of Lowell Farms Inc. “His extensive financial expertise and leadership across diverse industries make him the ideal addition to our team. Philippe’s proven ability to drive growth and innovation positions Lowell for an exciting new chapter as we continue to expand and elevate our presence in the cannabis industry.” Philippe Faraut is a highly accomplished financial executive with a dynamic career spanning multiple...

Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo, all administered once-weekly. The trial included 3,417 randomised people with obesity or overweight with one or more comorbidities and a mean baseline body weight of 106.9 kg. The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo. The REDEFINE 1 trial was based on a flexible protocol, allowing patients to modify their dosing throughout the trial....